{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:13:36Z","timestamp":1788898416146,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40264-023-01301-8","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T13:02:16Z","timestamp":1683118936000},"page":"553-563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results from a Prospective Observational Study in Priority Vaccinated Groups in North India"],"prefix":"10.1007","volume":"46","author":[{"given":"Upinder","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeba","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalika","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Sahni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol","family":"Dehade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju","family":"KL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish Kumar","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Kansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav","family":"Jaisawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7737-0016","authenticated-orcid":false,"given":"Sankha Shubhra","family":"Chakrabarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"1301_CR1","unstructured":"U.S. Food and Drug Administration. COVID-19 vaccines. [Internet]. 2021. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/covid-19-vaccines. Accessed 5 Jul 2021."},{"key":"1301_CR2","unstructured":"European Medicines Agency. COVID-19 Vaccines. 2021."},{"key":"1301_CR3","unstructured":"Press Information Bureau. Government of India. Press Statement by the Drugs Controller General of India (DCGI) on Restricted Emergency approval of COVID-19 virus vaccine. 2021."},{"key":"1301_CR4","doi-asserted-by":"crossref","unstructured":"Kaur U, Bala S, Joshi A, Reddy NTS, Japur C, Chauhan M, et al. Persistent Health Issues, Adverse Events, and Effectiveness of Vaccines during the Second Wave of COVID-19: A Cohort Study from a Tertiary Hospital in North India. Vaccines; 2022;10:1153. https:\/\/www.mdpi.com\/2076-393X\/10\/7\/1153. Accessed 24 Jul 2022.","DOI":"10.3390\/vaccines10071153"},{"key":"1301_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2034456","author":"P Behera","year":"2022","unstructured":"Behera P, Singh AK, Subba SH, Mc A, Sahu DP, Chandanshive PD, et al. Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India. Hum Vaccin Immunother. 2022. https:\/\/doi.org\/10.1080\/21645515.2022.2034456.","journal-title":"Hum Vaccin Immunother [Internet]."},{"key":"1301_CR6","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S1473-3099(21)00674-5","volume":"22","author":"D Desai","year":"2022","unstructured":"Desai D, Khan AR, Soneja M, Mittal A, Naik S, Kodan P, et al. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study. Lancet Infect Dis. 2022;22:349\u201356.","journal-title":"Lancet Infect Dis [Internet]."},{"key":"1301_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/imm.13443","volume":"165","author":"Y Chen","year":"2022","unstructured":"Chen Y, Xu Z, Wang P, Li X, Shuai Z, Ye D, et al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 2022;165:386\u2013401. https:\/\/doi.org\/10.1111\/imm.13443.","journal-title":"Immunology [Internet]."},{"key":"1301_CR8","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","volume":"384","author":"NH Schultz","year":"2021","unstructured":"Schultz NH, S\u00f8rvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384:2124\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2104882.","journal-title":"N Engl J Med [Internet]."},{"key":"1301_CR9","doi-asserted-by":"crossref","unstructured":"Singh R, Chakrabarti SS, Gambhir IS, Verma A, Kumar I, Ghosh S, et al. Acute Cardiac Events After ChAdOx1 nCoV-19 Corona Virus Vaccine: Report of Three Cases. Am J Ther. 2022;29:e579-e585. https:\/\/doi.org\/10.1097\/MJT.0000000000001472.","DOI":"10.1097\/MJT.0000000000001472"},{"key":"1301_CR10","unstructured":"Our World in Data. Coronavirus (COVID-19) Vaccinations [Internet]. https:\/\/ourworldindata.org\/covid-vaccinations?country=OWID_WRL. Accessed 29 Sep 2022."},{"key":"1301_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101038","volume":"38","author":"U Kaur","year":"2021","unstructured":"Kaur U, Ojha B, Pathak BK, Singh A, Giri KR, Singh A, et al. A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers- first results from India. EClinicalMedicine. 2021;38: 101038.","journal-title":"EClinicalMedicine [Internet]."},{"key":"1301_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/jmv.27320","volume":"94","author":"U Kaur","year":"2022","unstructured":"Kaur U, Bala S, Ojha B, Jaiswal S, Kansal S, Chakrabarti SS. Occurrence of COVID-19 in priority groups receiving ChAdOx1 nCoV-19 coronavirus vaccine (recombinant): a preliminary analysis from north India. J Med Virol. 2022;94:407\u201312.","journal-title":"J Med Virol"},{"key":"1301_CR13","unstructured":"SPEAC. SO2-D2.1.2 Priority List of COVID-19 Adverse events of special interest: Quarterly update. December 2020."},{"key":"1301_CR14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2108891","volume":"385","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021;385:585\u201394. https:\/\/doi.org\/10.1056\/NEJMoa2108891.","journal-title":"N Engl J Med [Internet]."},{"key":"1301_CR15","doi-asserted-by":"crossref","unstructured":"Tsang NNY, So HC, Cowling BJ, Leung GM, Ip DKM. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study. Lancet Infect Dis. 2022; https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473309922007320","DOI":"10.2139\/ssrn.4200539"},{"key":"1301_CR16","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med. 2022;386:1532\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2119451.","journal-title":"N Engl J Med [Internet]."},{"key":"1301_CR17","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet (London, England). 2021;397:881\u201391.","journal-title":"Lancet (London, England)."},{"key":"1301_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1088","volume":"373","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373: n1088.","journal-title":"BMJ [Internet]."},{"key":"1301_CR19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/ana.26143","volume":"90","author":"BV Maramattom","year":"2021","unstructured":"Maramattom BV, Krishnan P, Paul R, Padmanabhan S, CherukudalVishnuNampoothiri S, Syed AA, et al. Guillain-Barr\u00e9 syndrome following ChAdOx1-S\/nCoV-19 vaccine. Ann Neurol. 2021;90:312\u20134.","journal-title":"Ann Neurol Internet."},{"key":"1301_CR20","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1002\/jmv.27742","volume":"94","author":"R Singh","year":"2022","unstructured":"Singh R, Kaur U, Singh A, Chakrabarti SS. Refractory hypereosinophilia associated with newly diagnosed rheumatoid arthritis following inactivated BBV152 COVID-19 vaccine. J Med Virol. 2022;94:3482\u20137. https:\/\/doi.org\/10.1002\/jmv.27742.","journal-title":"J Med Virol [Internet]."},{"key":"1301_CR21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.14336\/AD.2021.1102","volume":"13","author":"SS Chakrabarti","year":"2022","unstructured":"Chakrabarti SS, Tiwari A, Jaiswal S, Kaur U, Kumar I, Mittal A, et al. Rapidly progressive dementia with asymmetric rigidity following ChAdOx1 nCoV-19 vaccination. Aging Dis. 2022;13:633\u20136. https:\/\/doi.org\/10.14336\/AD.2021.1102.","journal-title":"Aging Dis [Internet]."},{"key":"1301_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.919979\/full","author":"Y Xie","year":"2022","unstructured":"Xie Y, Liu Y, Liu Y. The flare of rheumatic disease after SARS-CoV-2 vaccination: a review. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.919979\/full.","journal-title":"Front Immunol [Internet]."},{"key":"1301_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001814","volume":"7","author":"SE Sattui","year":"2021","unstructured":"Sattui SE, Liew JW, Kennedy K, Sirotich E, Putman M, Moni TT, et al. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open. 2021;7: e001814. https:\/\/doi.org\/10.1136\/rmdopen-2021-001814.","journal-title":"RMD Open [Internet]."},{"key":"1301_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.617089\/full","author":"A Vojdani","year":"2021","unstructured":"Vojdani A, Vojdani E, Kharrazian D. Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2020.617089\/full.","journal-title":"Front Immunol [Internet]."},{"key":"1301_CR25","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1136\/annrheumdis-2021-221587","volume":"81","author":"F Ursini","year":"2022","unstructured":"Ursini F, Ruscitti P, Raimondo V, De Angelis R, Cacciapaglia F, Pigatto E, et al. Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases. Ann Rheum Dis. 2022;81:440\u20131. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221587.","journal-title":"Ann Rheum Dis [Internet]."},{"key":"1301_CR26","doi-asserted-by":"crossref","unstructured":"Sriwastava S, Sharma K, Khalid S, Bhansali S, Shrestha A, Elkhooly M, et al. COVID-19 vaccination and neurological manifestations: a review of case reports and case series. Brain Sci. 2022;12:407. https:\/\/www.mdpi.com\/2076-3425\/12\/3\/407","DOI":"10.3390\/brainsci12030407"},{"key":"1301_CR27","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/sj.gt.3302036","volume":"10","author":"Q Liu","year":"2003","unstructured":"Liu Q, Muruve DA. Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther. 2003;10:935\u201340.","journal-title":"Gene Ther [Internet]."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01301-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-023-01301-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01301-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T15:08:51Z","timestamp":1685113731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-023-01301-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1301"],"URL":"https:\/\/doi.org\/10.1007\/s40264-023-01301-8","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,3]]},"assertion":[{"value":"23 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding support.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests"}},{"value":"The study was conducted after permission from the Institute Ethical Committee of the Institute of Medical Sciences, Banaras Hindu University (Approval number Dean\/2021\/EC\/2526). No human experimentation was performed. All procedures were performed as per the Declaration of Helsinki and its subsequent modifications.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was taken from each participant for participating in the study","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data produced in the present study are available upon reasonable request to the authors, as per institutional and national legal norms and procedures.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: UK, SSC, SK, VJ. Methodology: UK, SSC, VJ. Formal analysis and investigation: UK, VJ, ZF, KM, VS, AD, KLA, AKY. Writing\u2014original draft preparation: UK, ZF. Writing\u2014review and editing: UK, SSC. Supervision: UK, SSC, SK. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}